Anxiolytic-like effects through a GLUK5 kainate receptor mechanism

Andrew Alt, Brianne Weiss, Paul L. Ornstein, Scott D. Gleason, David Bleakman, Robert Stratford Jr., Jeffrey M. Witkin

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The hypothesis that kainate receptor blockade would be associated with anxiolytic-like effects was tested with a selective ligand, 3S,4aR,6S,8aR-6-((4-carboxyphenyl)methyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid (LY382884). LY382884 selectively binds the GLUK5 kainate receptor subunit (Kb = 0.6 μM) and has 30 μM or greater affinity for cloned human AMPA receptor subtypes. The anxiolytic potential of LY382884 was tested in rats responding under a Vogel conflict procedure, a pharmacologically validated model for the prediction of antianxiety efficacy in humans. Both the benzodiazepine anxiolytic chlordiazepoxide and LY382884 increased suppressed licking without affecting rates of non-suppressed licking. In contrast, an AMPA receptor selective antagonist, 7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine-7-carboxamide, 5-(4-aminophenyl)-8,9-dihydro-N,8-dimethyl-, monohydrochloride (9CI) (GYKI53655), did not increase suppressed responding. The finding that a selective GLUK5 receptor antagonist produced anxiolytic-like effects in an animal model predictive of efficacy in humans combined with data in the literature on glutamatergic modulation of anxiety suggests that kainate receptor sensitivity to glutamate might be an important mediating event in the pathophysiological expression of anxiety states. The selective targeting of kainate receptors with an antagonist could therefore be a novel pharmacological mechanism to treat anxiety disorders.

Original languageEnglish (US)
Pages (from-to)1482-1487
Number of pages6
JournalNeuropharmacology
Volume52
Issue number7
DOIs
StatePublished - Jun 1 2007
Externally publishedYes

Fingerprint

LY382884
Kainic Acid Receptors
Anti-Anxiety Agents
AMPA Receptors
Benzodiazepines
Anxiety
Chlordiazepoxide
Anxiety Disorders
Glutamic Acid
Animal Models
Gluk1 kainate receptor
Pharmacology
Ligands

Keywords

  • AMPA receptors
  • Anxiolytic drugs
  • Chlordiazepoxide
  • GYKI53655
  • Kainate receptors
  • LY382884
  • Rats

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Drug Discovery
  • Pharmacology

Cite this

Alt, A., Weiss, B., Ornstein, P. L., Gleason, S. D., Bleakman, D., Stratford Jr., R., & Witkin, J. M. (2007). Anxiolytic-like effects through a GLUK5 kainate receptor mechanism. Neuropharmacology, 52(7), 1482-1487. https://doi.org/10.1016/j.neuropharm.2007.02.005

Anxiolytic-like effects through a GLUK5 kainate receptor mechanism. / Alt, Andrew; Weiss, Brianne; Ornstein, Paul L.; Gleason, Scott D.; Bleakman, David; Stratford Jr., Robert; Witkin, Jeffrey M.

In: Neuropharmacology, Vol. 52, No. 7, 01.06.2007, p. 1482-1487.

Research output: Contribution to journalArticle

Alt, A, Weiss, B, Ornstein, PL, Gleason, SD, Bleakman, D, Stratford Jr., R & Witkin, JM 2007, 'Anxiolytic-like effects through a GLUK5 kainate receptor mechanism', Neuropharmacology, vol. 52, no. 7, pp. 1482-1487. https://doi.org/10.1016/j.neuropharm.2007.02.005
Alt, Andrew ; Weiss, Brianne ; Ornstein, Paul L. ; Gleason, Scott D. ; Bleakman, David ; Stratford Jr., Robert ; Witkin, Jeffrey M. / Anxiolytic-like effects through a GLUK5 kainate receptor mechanism. In: Neuropharmacology. 2007 ; Vol. 52, No. 7. pp. 1482-1487.
@article{df88bb7287df4c98b8a36d2de1c38b3c,
title = "Anxiolytic-like effects through a GLUK5 kainate receptor mechanism",
abstract = "The hypothesis that kainate receptor blockade would be associated with anxiolytic-like effects was tested with a selective ligand, 3S,4aR,6S,8aR-6-((4-carboxyphenyl)methyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid (LY382884). LY382884 selectively binds the GLUK5 kainate receptor subunit (Kb = 0.6 μM) and has 30 μM or greater affinity for cloned human AMPA receptor subtypes. The anxiolytic potential of LY382884 was tested in rats responding under a Vogel conflict procedure, a pharmacologically validated model for the prediction of antianxiety efficacy in humans. Both the benzodiazepine anxiolytic chlordiazepoxide and LY382884 increased suppressed licking without affecting rates of non-suppressed licking. In contrast, an AMPA receptor selective antagonist, 7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine-7-carboxamide, 5-(4-aminophenyl)-8,9-dihydro-N,8-dimethyl-, monohydrochloride (9CI) (GYKI53655), did not increase suppressed responding. The finding that a selective GLUK5 receptor antagonist produced anxiolytic-like effects in an animal model predictive of efficacy in humans combined with data in the literature on glutamatergic modulation of anxiety suggests that kainate receptor sensitivity to glutamate might be an important mediating event in the pathophysiological expression of anxiety states. The selective targeting of kainate receptors with an antagonist could therefore be a novel pharmacological mechanism to treat anxiety disorders.",
keywords = "AMPA receptors, Anxiolytic drugs, Chlordiazepoxide, GYKI53655, Kainate receptors, LY382884, Rats",
author = "Andrew Alt and Brianne Weiss and Ornstein, {Paul L.} and Gleason, {Scott D.} and David Bleakman and {Stratford Jr.}, Robert and Witkin, {Jeffrey M.}",
year = "2007",
month = "6",
day = "1",
doi = "10.1016/j.neuropharm.2007.02.005",
language = "English (US)",
volume = "52",
pages = "1482--1487",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - Anxiolytic-like effects through a GLUK5 kainate receptor mechanism

AU - Alt, Andrew

AU - Weiss, Brianne

AU - Ornstein, Paul L.

AU - Gleason, Scott D.

AU - Bleakman, David

AU - Stratford Jr., Robert

AU - Witkin, Jeffrey M.

PY - 2007/6/1

Y1 - 2007/6/1

N2 - The hypothesis that kainate receptor blockade would be associated with anxiolytic-like effects was tested with a selective ligand, 3S,4aR,6S,8aR-6-((4-carboxyphenyl)methyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid (LY382884). LY382884 selectively binds the GLUK5 kainate receptor subunit (Kb = 0.6 μM) and has 30 μM or greater affinity for cloned human AMPA receptor subtypes. The anxiolytic potential of LY382884 was tested in rats responding under a Vogel conflict procedure, a pharmacologically validated model for the prediction of antianxiety efficacy in humans. Both the benzodiazepine anxiolytic chlordiazepoxide and LY382884 increased suppressed licking without affecting rates of non-suppressed licking. In contrast, an AMPA receptor selective antagonist, 7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine-7-carboxamide, 5-(4-aminophenyl)-8,9-dihydro-N,8-dimethyl-, monohydrochloride (9CI) (GYKI53655), did not increase suppressed responding. The finding that a selective GLUK5 receptor antagonist produced anxiolytic-like effects in an animal model predictive of efficacy in humans combined with data in the literature on glutamatergic modulation of anxiety suggests that kainate receptor sensitivity to glutamate might be an important mediating event in the pathophysiological expression of anxiety states. The selective targeting of kainate receptors with an antagonist could therefore be a novel pharmacological mechanism to treat anxiety disorders.

AB - The hypothesis that kainate receptor blockade would be associated with anxiolytic-like effects was tested with a selective ligand, 3S,4aR,6S,8aR-6-((4-carboxyphenyl)methyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid (LY382884). LY382884 selectively binds the GLUK5 kainate receptor subunit (Kb = 0.6 μM) and has 30 μM or greater affinity for cloned human AMPA receptor subtypes. The anxiolytic potential of LY382884 was tested in rats responding under a Vogel conflict procedure, a pharmacologically validated model for the prediction of antianxiety efficacy in humans. Both the benzodiazepine anxiolytic chlordiazepoxide and LY382884 increased suppressed licking without affecting rates of non-suppressed licking. In contrast, an AMPA receptor selective antagonist, 7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine-7-carboxamide, 5-(4-aminophenyl)-8,9-dihydro-N,8-dimethyl-, monohydrochloride (9CI) (GYKI53655), did not increase suppressed responding. The finding that a selective GLUK5 receptor antagonist produced anxiolytic-like effects in an animal model predictive of efficacy in humans combined with data in the literature on glutamatergic modulation of anxiety suggests that kainate receptor sensitivity to glutamate might be an important mediating event in the pathophysiological expression of anxiety states. The selective targeting of kainate receptors with an antagonist could therefore be a novel pharmacological mechanism to treat anxiety disorders.

KW - AMPA receptors

KW - Anxiolytic drugs

KW - Chlordiazepoxide

KW - GYKI53655

KW - Kainate receptors

KW - LY382884

KW - Rats

UR - http://www.scopus.com/inward/record.url?scp=34247571364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247571364&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2007.02.005

DO - 10.1016/j.neuropharm.2007.02.005

M3 - Article

C2 - 17418283

AN - SCOPUS:34247571364

VL - 52

SP - 1482

EP - 1487

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 7

ER -